Market capitalization | $7.51b |
Enterprise Value | $11.10b |
P/E (TTM) P/E ratio | 17.90 |
EV/FCF (TTM) EV/FCF | 9.82 |
EV/Sales (TTM) EV/Sales | 2.78 |
P/S ratio (TTM) P/S ratio | 1.88 |
P/B ratio (TTM) P/B ratio | 1.80 |
Revenue growth (TTM) Revenue growth | 5.23% |
Revenue (TTM) Revenue | $3.99b |
As a Free StocksGuide user, you can view scores for all 6,892 stocks worldwide.
21 Analysts have issued a Jazz Pharmaceuticals Plc forecast:
21 Analysts have issued a Jazz Pharmaceuticals Plc forecast:
Sep '24 |
+/-
%
|
||
Revenue | 3,993 3,993 |
5%
5%
|
|
Gross Profit | 2,949 2,949 |
9%
9%
|
|
EBITDA | 1,389 1,389 |
16%
16%
|
EBIT (Operating Income) EBIT | 738 738 |
30%
30%
|
Net Profit | 463 463 |
479%
479%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Jazz Pharmaceuticals Plc operates as a specialty biopharmaceutical company, which focuses on the identification, development and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain and psychiatry. Its product portfolio includes: XYREM, ERWINAZETM, PRIALT, intrathecal infusion, FAZACLO and LUVOX CR. The company was founded by Bruce C. Cozadd in March 2003 and is headquartered in Dublin, Ireland.
Head office | Ireland |
CEO | Bruce Cozadd |
Employees | 2,800 |
Founded | 2005 |
Website | www.jazzpharmaceuticals.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.